Gèrard Socié

Active 1989–2025

Also published as
Gérard Socié · Gerard Socié · Gerard Socie
348
Papers
54,866
Citations
127
h-index
332
i10-index

Citations

Citations per year for Gèrard Socié1983: 4 citations1989: 2 citations1990: 2 citations1991: 5 citations1992: 6 citations1993: 14 citations1994: 12 citations1995: 23 citations1996: 35 citations1997: 30 citations1998: 46 citations1999: 75 citations2000: 120 citations2001: 104 citations2002: 155 citations2003: 189 citations2004: 131 citations2005: 173 citations2006: 160 citations2007: 241 citations2008: 255 citations2009: 300 citations2010: 342 citations2011: 431 citations2012: 322 citations2013: 362 citations2014: 367 citations2015: 435 citations2016: 410 citations2017: 408 citations2018: 311 citations2019: 1,283 citations2020: 1,596 citations2021: 1,401 citations2022: 1,194 citations2023: 815 citations2024: 1,594 citations2025: 502 citations2026: 4 citations1984–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,269 citing papers, 25% of this breakdownFrance: 1,331 citing papers, 7.8% of this breakdownGermany: 1,305 citing papers, 7.7% of this breakdownUnited Kingdom: 1,197 citing papers, 7% of this breakdownItaly: 1,085 citing papers, 6.4% of this breakdownChina: 716 citing papers, 4.2% of this breakdownSpain: 609 citing papers, 3.6% of this breakdownNetherlands: 595 citing papers, 3.5% of this breakdownCanada: 535 citing papers, 3.1% of this breakdownSwitzerland: 509 citing papers, 3% of this breakdownJapan: 509 citing papers, 3% of this breakdownAustralia: 360 citing papers, 2.1% of this breakdown
0%25%Other 23.6%

Fields

  • Medicine75.8%
  • Immunology and Microbiology11.6%
  • Biochemistry, Genetics and Molecular Biology10.7%
  • Neuroscience0.3%
  • Environmental Science0.3%
  • Agricultural and Biological Sciences0.2%
  • Other1.1%

Topics

  • Hematopoietic Stem Cell Transplantation12.8%
  • Acute Myeloid Leukemia Research5.8%
  • Immune Cell Function and Interaction3.6%
  • Acute Lymphoblastic Leukemia research3.6%
  • T-cell and B-cell Immunology2.9%
  • Complement system in diseases2.4%
  • Other68.9%

Coauthors

All papers

Open in search
  1. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 865

  2. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2005 cited by 3,530

  3. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2020 cited by 538

  4. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2006 cited by 1,272

  5. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Αthanasios Fassas, Andrea Himsel, David Launay, Andrea Lo Monaco, Pierre Philippe, I. Quéré, Éric Rich, René Westhovens, Bridget Griffiths, Riccardo Saccardi, F.H.J. van den Hoogen, Willem E. Fibbe, Gèrard Socié, Aloïs Gratwohl, A Tyndall - JAMA 2014 cited by 744

  6. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alain Fischer, Kenneth Cornetta, F. Galactéros, Yves Beuzard, Éliane Gluckman, Frederic D. Bushman, Salima Hacein‐Bey‐Abina, Philippe Leboulch - Nature 2010 cited by 1,274

  7. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Serena Marotta, Talha Munir, Jennifer M.L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clément, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Fabiana Cacace, Camilla Frieri, M. Van Lint, Jakob Passweg, Judith Marsh, Gèrard Socié, Ghulam J. Mufti, Carlo Dufour, Antonio M. Risitano - New England Journal of Medicine 2022 cited by 298

  8. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 133

  9. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Peter Gale, John Koreth, Nelson J. Chao, Mahmoud Aljurf, Brenda Cooper, Mary J. Laughlin, Jack W. Hsu, Peiman Hematti, Leo F. Verdonck, Melhelm M. Solh, Maxim Norkin, Vijay Reddy, Rodrigo Martino, Shahinaz M. Gadalla, Jenna D. Goldberg, Philip L. McCarthy, Josè Antonio Pérez-Simón, Nandita Khera, Ian D. Lewis, Yoshiko Atsuta, Richard F. Olsson, Wael Saber, Edmund K. Waller, Didier Blaise, Joseph A. Pidala, Paul J. Martin, Prakash Satwani, Martin Bornhäuser, Yoshihiro Inamoto, Daniel J. Weisdorf, Mary M. Horowitz, Steven Z. Pavletic - Biology of Blood and Marrow Transplantation 2014 cited by 435

  10. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hildegard Greinix, Stefanie Sarantopoulos, Gèrard Socié, Bruce R. Blazar, Joseph Pidala, Carrie L. Kitko, Daniel R. Couriel, Corey Cutler, Kirk R. Schultz, Steven Z. Pavletic, Stephanie J. Lee, Sophie Paczesny - Transplantation and Cellular Therapy 2021 cited by 143

  11. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2009 cited by 719

  12. Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 627

  13. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fabio Ciceri, Jaime Sanz, Ali Bazarbachi, Arnon Nagler, Mohamad Mohty - Bone Marrow Transplantation 2020 cited by 203

  14. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

    Authors: , , , , , , , , , - British Journal of Haematology 2019 cited by 233

  15. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Guido Kobbe, Markus Wiesneth, Michael Koldehoff, Gèrard Socié, Nicolaus Kröger, Lars Bullinger, Christian Thiede, Frédérik Damm - Journal of Clinical Oncology 2018 cited by 220

  16. Germline DDX41 mutations define a significant entity within adult MDS/AML patients

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2019 cited by 209

  17. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2021 cited by 167

  18. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Arnaud Petit, Guy Leverger, Gérard Michel, Yves Bertrand, André Baruchel, Gérard Socié, Jean Soulier - Blood 2017 cited by 342

  19. In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4 + T H 1 cell response

    Authors: , , , , , , , , , , , , , , , - Science Immunology 2021 cited by 74

  20. A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality

    Authors: , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 cited by 279

  21. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation

    Authors: , , , , , , , , , , , , , - Blood 2019 cited by 180

  22. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria

    Authors: , , , , , , , , , , , , , , , - Blood 2007 cited by 578

  23. Bone Marrow Failure in Fanconi Anemia Is Triggered by an Exacerbated p53/p21 DNA Damage Response that Impairs Hematopoietic Stem and Progenitor Cells

    Authors: , , , , , , , , , , , , , , , , , , - Cell stem cell 2012 cited by 341

  24. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites

    Authors: , , , , , , , , , , , - Nature Communications 2019 cited by 139